Association of metabolic dysfunction with cognitive decline and Alzheimer's disease: A review of metabolomic evidence

[1]  Eosu Kim,et al.  Plasma adiponectin levels predict cognitive decline and cortical thinning in mild cognitive impairment with beta-amyloid pathology , 2022, Alzheimer's Research & Therapy.

[2]  H. Abdelhady,et al.  Comparison of Tau and Amyloid-β Targeted Immunotherapy Nanoparticles for Alzheimer’s Disease , 2022, Biomolecules.

[3]  S. Sungkarat,et al.  Obesity and Brain Health: The Impact of Metabolic Syndrome and Cardiorespiratory Fitness on Cognitive Performances in Middle-Aged Obese Women , 2022, The Journal of Prevention of Alzheimer's Disease.

[4]  Debasmita Dutta,et al.  Metabolic disorder in Alzheimer’s disease , 2021, Metabolic Brain Disease.

[5]  A. Yilmaz,et al.  Targeted Metabolic Profiling of Urine Highlights a Potential Biomarker Panel for the Diagnosis of Alzheimer’s Disease and Mild Cognitive Impairment: A Pilot Study , 2020, Metabolites.

[6]  Xianlin Han,et al.  Peripheral serum metabolomic profiles inform central cognitive impairment , 2020, Scientific Reports.

[7]  Xiulian Sun,et al.  Serum metabolomic profiling in patients with Alzheimer Disease and Amnestic Mild Cognitive Impairment by GC/MS. , 2020, Biomedical chromatography : BMC.

[8]  G. Paolisso,et al.  Adiponectin and Cognitive Decline , 2020, International journal of molecular sciences.

[9]  L. Tan,et al.  A panel of blood lipids associated with cognitive performance, brain atrophy, and Alzheimer's diagnosis: A longitudinal study of elders without dementia , 2020, Alzheimer's & dementia.

[10]  Dean P. Jones,et al.  High‐resolution metabolomic profiling of Alzheimer’s disease in plasma , 2019, Annals of clinical and translational neurology.

[11]  M. Liu,et al.  Elevated serum TC and LDL-C levels in Alzheimer’s disease and mild cognitive impairment: A meta-analysis study , 2019, Brain Research.

[12]  M. Cheng,et al.  The Differences of Serum Metabolites Between Patients With Early-Stage Alzheimer's Disease and Mild Cognitive Impairment , 2019, Front. Neurol..

[13]  S. Larsson,et al.  Polyunsaturated fatty acids and risk of Alzheimer’s disease: a Mendelian randomization study , 2019, European Journal of Nutrition.

[14]  A. Gamian,et al.  Targeted metabolomic analysis of nitric oxide/L-arginine pathway metabolites in dementia: association with pathology, severity, and structural brain changes , 2019, Scientific Reports.

[15]  Piyush Gondaliya,et al.  Cognitive dysfunction: A growing link between diabetes and Alzheimer's disease , 2019, Drug development research.

[16]  Xianlin Han,et al.  Association of Altered Liver Enzymes With Alzheimer Disease Diagnosis, Cognition, Neuroimaging Measures, and Cerebrospinal Fluid Biomarkers , 2019, JAMA network open.

[17]  L. Mandelli,et al.  Metabolic Syndrome, Mild Cognitive Impairment, and Dementia: A Meta-Analysis of Longitudinal Studies. , 2019, The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry.

[18]  K. Blennow,et al.  Primary fatty amides in plasma associated with brain amyloid burden, hippocampal volume, and memory in the European Medical Information Framework for Alzheimer’s Disease biomarker discovery cohort , 2019, Alzheimer's & Dementia.

[19]  Ru-jing Ren,et al.  Dysregulated Urinary Arginine Metabolism in Older Adults With Amnestic Mild Cognitive Impairment , 2019, Front. Aging Neurosci..

[20]  Li Jin,et al.  Metabolomics in the Development and Progression of Dementia: A Systematic Review , 2019, Front. Neurosci..

[21]  F. D. De Felice,et al.  The Role of Leptin and Adiponectin in Obesity-Associated Cognitive Decline and Alzheimer’s Disease , 2019, Front. Neurosci..

[22]  J. Fontecha,et al.  Activities, bioavailability, and metabolism of lipids from structural membranes and oils: Promising research on mild cognitive impairment , 2018, Pharmacological research.

[23]  J. Han,et al.  Aging and Alzheimer’s disease: Comparison and associations from molecular to system level , 2018, Aging cell.

[24]  J. Clarke,et al.  Metabolic Dysfunction in Alzheimer's Disease: From Basic Neurobiology to Clinical Approaches. , 2018, Journal of Alzheimer's disease : JAD.

[25]  Xianlin Han,et al.  Altered bile acid profile in mild cognitive impairment and Alzheimer's disease: Relationship to neuroimaging and CSF biomarkers , 2018, Alzheimer's & Dementia.

[26]  Xianlin Han,et al.  Altered bile acid profile associates with cognitive impairment in Alzheimer's disease—An emerging role for gut microbiome , 2018, Alzheimer's & Dementia.

[27]  A. Saykin,et al.  Brain and blood metabolite signatures of pathology and progression in Alzheimer disease: A targeted metabolomics study , 2018, PLoS medicine.

[28]  Michael W. Weiner,et al.  Metabolic network failures in Alzheimer's disease: A biochemical road map , 2017, Alzheimer's & Dementia.

[29]  C. Sánchez-Torres,et al.  Metabolic Syndrome as a Risk Factor for Alzheimer's Disease: Is Aβ a Crucial Factor in Both Pathologies? , 2017, Antioxidants & redox signaling.

[30]  A. Oliveira‐Brett,et al.  Alzheimer's disease amyloid beta peptides in vitro electrochemical oxidation. , 2017, Bioelectrochemistry.

[31]  Y. An,et al.  Association between fatty acid metabolism in the brain and Alzheimer disease neuropathology and cognitive performance: A nontargeted metabolomic study , 2017, PLoS medicine.

[32]  Michelle K. Lupton,et al.  Association of blood lipids with Alzheimer's disease: A comprehensive lipidomics analysis , 2017, Alzheimer's & Dementia.

[33]  Cindee M. Madison,et al.  Dynamic relationships between age, amyloid-β deposition, and glucose metabolism link to the regional vulnerability to Alzheimer's disease. , 2016, Brain : a journal of neurology.

[34]  M. Kraut,et al.  Blood metabolite markers of cognitive performance and brain function in aging , 2016, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[35]  S. Patassini,et al.  Graded perturbations of metabolism in multiple regions of human brain in Alzheimer's disease: Snapshot of a pervasive metabolic disorder , 2016, Biochimica et biophysica acta.

[36]  C. Barbas,et al.  Metabolomic-Driven Elucidation of Serum Disturbances Associated with Alzheimer's Disease and Mild Cognitive Impairment. , 2016, Current Alzheimer research.

[37]  Sharon S. Simon,et al.  Cognitive Effects of Intentional Weight Loss in Elderly Obese Individuals With Mild Cognitive Impairment. , 2016, The Journal of clinical endocrinology and metabolism.

[38]  Guojun Bu,et al.  Implications of GABAergic Neurotransmission in Alzheimer’s Disease , 2016, Front. Aging Neurosci..

[39]  T. Gasser,et al.  Fruit flies, bile acids, and Parkinson disease , 2015, Neurology.

[40]  Bixente Dilharreguy,et al.  Mediterranean diet and preserved brain structural connectivity in older subjects , 2015, Alzheimer's & Dementia.

[41]  A. Biswas,et al.  Metabolic Risk Factors of Sporadic Alzheimer's Disease: Implications in the Pathology, Pathogenesis and Treatment. , 2015, Aging and disease.

[42]  D. Corella,et al.  Mediterranean Diet and Age-Related Cognitive Decline: A Randomized Clinical Trial. , 2015, JAMA internal medicine.

[43]  E. Feldman,et al.  Insulin resistance as a key link for the increased risk of cognitive impairment in the metabolic syndrome , 2015, Experimental & Molecular Medicine.

[44]  J. Gómez-Ariza,et al.  Metabolomic screening of regional brain alterations in the APP/PS1 transgenic model of Alzheimer's disease by direct infusion mass spectrometry. , 2015, Journal of pharmaceutical and biomedical analysis.

[45]  R. Petersen,et al.  Mild cognitive impairment and mild dementia: a clinical perspective. , 2014, Mayo Clinic proceedings.

[46]  Liyan Liu,et al.  Lysophosphatidylcholine and Amide as Metabolites for Detecting Alzheimer Disease Using Ultrahigh-Performance Liquid Chromatography–Quadrupole Time-of-Flight Mass Spectrometry–Based Metabonomics , 2014, Journal of neuropathology and experimental neurology.

[47]  D. Gustafson,et al.  Adipokines: a link between obesity and dementia? , 2014, The Lancet Neurology.

[48]  J L Gómez-Ariza,et al.  Metabolomic study of lipids in serum for biomarker discovery in Alzheimer's disease using direct infusion mass spectrometry. , 2014, Journal of pharmaceutical and biomedical analysis.

[49]  M. Mielke,et al.  Recent advances in the application of metabolomics to Alzheimer's Disease. , 2014, Biochimica et biophysica acta.

[50]  Cindee M. Madison,et al.  Is verbal episodic memory in elderly with amyloid deposits preserved through altered neuronal function? , 2014, Cerebral cortex.

[51]  S. M. de la Monte,et al.  Brain metabolic dysfunction at the core of Alzheimer's disease. , 2014, Biochemical pharmacology.

[52]  H. Soininen,et al.  Evidence of altered phosphatidylcholine metabolism in Alzheimer's disease , 2014, Neurobiology of Aging.

[53]  Filippo Caraci,et al.  Searching for disease-modifying drugs in AD: can we combine neuropsychological tools with biological markers? , 2014, CNS & neurological disorders drug targets.

[54]  Cindee M. Madison,et al.  Covarying alterations in Aβ deposition, glucose metabolism, and gray matter volume in cognitively normal elderly , 2014, Human brain mapping.

[55]  David S Knopman,et al.  Classification and epidemiology of MCI. , 2013, Clinics in geriatric medicine.

[56]  T. Toyo’oka,et al.  Metabolic profiling of Alzheimer's disease brains , 2013, Scientific Reports.

[57]  L. Mosconi,et al.  Glucose metabolism in normal aging and Alzheimer’s disease: methodological and physiological considerations for PET studies , 2013, Clinical and Translational Imaging.

[58]  Ronald C. Petersen,et al.  Identification of Altered Metabolic Pathways in Plasma and CSF in Mild Cognitive Impairment and Alzheimer’s Disease Using Metabolomics , 2013, PloS one.

[59]  Noffisat O. Oki,et al.  Alterations in metabolic pathways and networks in Alzheimer's disease , 2013, Translational Psychiatry.

[60]  J. Martínez,et al.  Virgin olive oil supplementation and long-term cognition: the Predimed-Navarra randomized, trial , 2013, The journal of nutrition, health & aging.

[61]  G. Taibi,et al.  Alzheimer’s disease: amino acid levels and brain metabolic status , 2013, Neurological Sciences.

[62]  A. Wimo,et al.  The global prevalence of dementia: A systematic review and metaanalysis , 2013, Alzheimer's & Dementia.

[63]  G. Siuzdak,et al.  Innovation: Metabolomics: the apogee of the omics trilogy , 2012, Nature Reviews Molecular Cell Biology.

[64]  H. Soininen,et al.  Metabolome in progression to Alzheimer's disease , 2011, Translational Psychiatry.

[65]  H. Tanila,et al.  From brain to food: analysis of phosphatidylcholins, lyso-phosphatidylcholins and phosphatidylcholin-plasmalogens derivates in Alzheimer's disease human post mortem brains and mice model via mass spectrometry. , 2011, Journal of chromatography. A.

[66]  B. Winblad,et al.  Analysis of chiral amino acids in cerebrospinal fluid samples linked to different stages of Alzheimer disease , 2011, Electrophoresis.

[67]  Arturo Pujia,et al.  Possible implications of insulin resistance and glucose metabolism in Alzheimer’s disease pathogenesis , 2011, Journal of cellular and molecular medicine.

[68]  Xianlin Han,et al.  Metabolomics in Early Alzheimer's Disease: Identification of Altered Plasma Sphingolipidome Using Shotgun Lipidomics , 2011, PloS one.

[69]  Cindee M. Madison,et al.  Associations between cognitive, functional, and FDG-PET measures of decline in AD and MCI , 2011, Neurobiology of Aging.

[70]  R. Rozmahel,et al.  Oleic Acid Ameliorates Amyloidosis in Cellular and Mouse Models of Alzheimer's Disease , 2011, Brain pathology.

[71]  M. Péter,et al.  Docosahexaenoic Acid Reduces Amyloid β Production via Multiple Pleiotropic Mechanisms* , 2011, The Journal of Biological Chemistry.

[72]  Dimitrios Kapogiannis,et al.  Disrupted energy metabolism and neuronal circuit dysfunction in cognitive impairment and Alzheimer's disease , 2011, The Lancet Neurology.

[73]  Ken Aoshima,et al.  Quantitative and wide-ranging profiling of phospholipids in human plasma by two-dimensional liquid chromatography/mass spectrometry. , 2010, Analytical chemistry.

[74]  Daniele Sancarlo,et al.  Metabolic-cognitive syndrome: A cross-talk between metabolic syndrome and Alzheimer's disease , 2010, Ageing Research Reviews.

[75]  A. Copani,et al.  Alzheimer's disease: brain expression of a metabolic disorder? , 2010, Trends in Endocrinology & Metabolism.

[76]  Xianlin Han.  Multi-dimensional mass spectrometry-based shotgun lipidomics and the altered lipids at the mild cognitive impairment stage of Alzheimer's disease. , 2010, Biochimica et biophysica acta.

[77]  P. He,et al.  Plasma metabolic profiling of Alzheimer's disease by liquid chromatography/mass spectrometry. , 2010, Clinical biochemistry.

[78]  J. A. Menéndez,et al.  Olive oil and health: summary of the II international conference on olive oil and health consensus report, Jaén and Córdoba (Spain) 2008. , 2010, Nutrition, metabolism, and cardiovascular diseases : NMCD.

[79]  G. Cole,et al.  DHA may prevent age-related dementia. , 2010, The Journal of nutrition.

[80]  M. Mattson,et al.  “Control” laboratory rodents are metabolically morbid: Why it matters , 2010, Proceedings of the National Academy of Sciences.

[81]  P. Barberger-Gateau,et al.  Fish, docosahexaenoic acid and Alzheimer's disease. , 2009, Progress in lipid research.

[82]  S. M. de la Monte,et al.  Insulin resistance and Alzheimer's disease. , 2009, BMB reports.

[83]  Rima Kaddurah-Daouk,et al.  Metabolomics tools for identifying biomarkers for neuropsychiatric diseases , 2009, Neurobiology of Disease.

[84]  Madhav Thambisetty,et al.  A proposed metabolic strategy for monitoring disease progression in Alzheimer's disease , 2009, Electrophoresis.

[85]  Suzanne Craft,et al.  The role of metabolic disorders in Alzheimer disease and vascular dementia: two roads converged. , 2009, Archives of neurology.

[86]  Christoph Lange,et al.  Genome-wide association analysis reveals putative Alzheimer's disease susceptibility loci in addition to APOE. , 2008, American journal of human genetics.

[87]  L. Mucke,et al.  Phospholipase A2 reduction ameliorates cognitive deficits in a mouse model of Alzheimer's disease , 2008, Nature Neuroscience.

[88]  G. Pasinetti,et al.  Metabolic syndrome and the role of dietary lifestyles in Alzheimer’s disease , 2008, Journal of neurochemistry.

[89]  Dana Dabelea,et al.  The metabolic syndrome. , 2008, Endocrine reviews.

[90]  M. G. Harrington,et al.  Free amino acid and dipeptide changes in the body fluids from Alzheimer’s disease subjects , 2007, Amino Acids.

[91]  Rhoda Au,et al.  Plasma phosphatidylcholine docosahexaenoic acid content and risk of dementia and Alzheimer disease: the Framingham Heart Study. , 2006, Archives of neurology.

[92]  G. Cole,et al.  Docosahexaenoic Acid Protects from Amyloid and Dendritic Pathology in an Alzheimer's Disease Mouse Model , 2006, Nutrition and health.

[93]  F. Pasquier,et al.  Lipid lowering agents are associated with a slower cognitive decline in Alzheimer’s disease , 2005, Journal of Neurology, Neurosurgery & Psychiatry.

[94]  B. Strooper,et al.  Regulation of cholesterol and sphingomyelin metabolism by amyloid-β and presenilin , 2005, Nature Cell Biology.

[95]  D. Schubert.  Glucose metabolism and Alzheimer's disease , 2005, Ageing Research Reviews.

[96]  Kristine Yaffe,et al.  Obesity in middle age and future risk of dementia: a 27 year longitudinal population based study , 2005, BMJ : British Medical Journal.

[97]  R. Petersen.  Mild cognitive impairment as a diagnostic entity , 2004, Journal of internal medicine.

[98]  M. Albert,et al.  Amnestic MCI or prodromal Alzheimer's disease? , 2004, The Lancet Neurology.

[99]  M. Mattson,et al.  Involvement of oxidative stress-induced abnormalities in ceramide and cholesterol metabolism in brain aging and Alzheimer's disease , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[100]  J R Hodges,et al.  Retrosplenial cortex (BA 29/30) hypometabolism in mild cognitive impairment (prodromal Alzheimer's disease) , 2003, The European journal of neuroscience.

[101]  L. Thal,et al.  Mild hypercholesterolemia is an early risk factor for the development of Alzheimer amyloid pathology , 2003, Neurology.

[102]  R. Kolesnick.  The therapeutic potential of modulating the ceramide/sphingomyelin pathway. , 2002, The Journal of clinical investigation.

[103]  Y. Ishibashi,et al.  Docosahexaenoic acid provides protection from impairment of learning ability in Alzheimer's disease model rats , 2002, Journal of neurochemistry.

[104]  J. Joseph,et al.  Essential fatty acids and the brain: possible health implications , 2000, International Journal of Developmental Neuroscience.

[105]  J. Haines,et al.  Effects of Age, Sex, and Ethnicity on the Association Between Apolipoprotein E Genotype and Alzheimer Disease: A Meta-analysis , 1997 .

[106]  N. Foster,et al.  Metabolic reduction in the posterior cingulate cortex in very early Alzheimer's disease , 1997, Annals of neurology.

[107]  J. Haines,et al.  Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. , 1993, Science.

[108]  M. Pericak-Vance,et al.  Apolipoprotein E: high-avidity binding to beta-amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer disease. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[109]  Satoshi Takahashi,et al.  A significant reduction of putative transmitter amino acids in cerebrospinal fluid of patients with Parkinson's disease and spinocerebellar degeneration , 1991, Neuroscience Letters.

[110]  Stuart Maudsley,et al.  Metabolic dysfunction in Alzheimer's disease and related neurodegenerative disorders. , 2012, Current Alzheimer research.

[111]  Danielle Swanson,et al.  Omega-3 fatty acids EPA and DHA: health benefits throughout life. , 2012, Advances in nutrition.

[112]  J. Schneider,et al.  Plasma and brain fatty acid profiles in mild cognitive impairment and Alzheimer's disease. , 2012, Journal of Alzheimer's disease : JAD.

[113]  T. Tabira,et al.  Urinary homocysteic acid levels correlate with mini-mental state examination scores in Alzheimer's disease patients. , 2012, Journal of Alzheimer's disease : JAD.

[114]  F. Jessen,et al.  Dimethylarginines, homocysteine metabolism, and cerebrospinal fluid markers for Alzheimer's disease. , 2012, Journal of Alzheimer's disease : JAD.

[115]  Rima Kaddurah-Daouk,et al.  Metabolomics: A Global Biochemical Approach to the Study of Central Nervous System Diseases , 2009, Neuropsychopharmacology.

[116]  A. Passmore,et al.  Untargeted Metabolomic Analysis of Human Plasma Indicates Differentially Affected Polyamine and L-Arginine Metabolism in Mild Cognitive Impairment Subjects Converting to Alzheimer’s Disease , 2015, PloS one.

[117]  O. Fiehn.  Metabolomics – the link between genotypes and phenotypes , 2004, Plant Molecular Biology.

[118]  K. Heininger,.  A Unifying Hypothesis of Alzheimer's Disease. IV. Causation and Sequence of Events , 2000, Reviews in the neurosciences.

[119]  Shuzhao Li,et al.  Computational Metabolomics: A Framework for the Million Metabolome , 2022 .